We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » FDA Issues Final Guidance for ANDA/PAS Amendments Under GDUFA II
FDA Issues Final Guidance for ANDA/PAS Amendments Under GDUFA II
The FDA released final guidance Tuesday spelling out its review goals for amendments to abbreviated new drug applications and prior approval supplements under GDUFA II.